---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-105634"
form_type: "8-K"
ticker: "TOVX"
cik: "0000894158"
company_name: "Theriva Biologics, Inc."
filed_at: "2024-10-03T23:59:59+00:00"
generated_at: "2026-05-30T21:56:08.722157+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Theriva Biologics DSMC recommends advancing SYN-004 trial to Cohort 3 after positive Cohort 2 safety data

## Summary
- DSMC reviewed safety and PK data from Cohort 2 (19 patients) and recommended study proceed to Cohort 3 using cefepime.
- No SAEs or AEs determined related to study drug; 15 SAEs reported among 10 patients typical for allo-HCT.
- No patient blood samples positive for SYN-004 at any timepoint; piperacillin PK as expected.
- Company pursuing additional funding to enable Cohort 3 conduct; Phase 1b/2a trial remains blinded.

## SEC filing metadata
- accession: 0001104659-24-105634
- form_type: 8-K
- ticker: TOVX
- cik: 0000894158
- company_name: Theriva Biologics, Inc.
- filed_at: 2024-10-03T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/894158/000110465924105634/0001104659-24-105634-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/894158/000110465924105634/tm2425487d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-105634
- JSON: https://secwatch.observer/filing/0001104659-24-105634.json
- Plain text: https://secwatch.observer/filing/0001104659-24-105634.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.